ILMN - Illumina Platform Price-to-Projected Revenue Ratio

Graphic logo of Illumina, Inc. (ILMN)

The forward P/S ratio of Illumina, Inc. (ILMN) correlates with the operations of sterile plants in Singapore, the US, and the UK. The implementation of autonomous robotic biomaterial analyzers optimizes processes, while the 6.60 mark indicates the level of market expectations. The business relies on its monopoly in DNA sequencing, generating revenue through the recurring sale of high-cost reagents for mass diagnostics.

ILMN (Illumina) Forward P/S Multiple history from 07/04/2022 to 11/15/2026

Analytical breakdowns for Illumina, Inc.

- market price and analyst price targets:
- market capitalization statistics:
Fundamental company valuation:Illumina Inc ILMN
Product sample of Illumina, Inc.

For Illumina, Inc. (ILMN), which is protected by unique DNA sequencing patents, the forward P/S ratio serves as an indicator of revenue resilience in the face of regulatory pressure. This metric compares current market value with expected sales, making it possible to identify systemic business degradation behind the apparent cheapness of the asset. The 6.60 value on the chart determines the extent to which the market is willing to pay a premium for future growth amid stringent antitrust restrictions.

Competitors of Illumina, Inc.

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|Exact Sciences Inc. - Forward P/S Multiple|RVTY: Price-to-Projected Revenue Ratio|Bio-Rad (BIO) - Price-to-Projected Revenue Ratio|NNNN - Market Cap to Expected Sales Ratio|SHC (Sotera Health Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio QuidelOrtho Inc. QDEL|Forward P/S Multiple OPK|CareDx - Market Cap to Projected Revenue|Forward P/S Multiple MRVI (Maravai LifeSciences Holdings)|Price to Expected Revenue Ratio FLGT (Fulgent Corp)|LAB: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Cytek Corp CTKB|OSUR (OraSure Technologies Inc) - Forward Price-to-Revenue Multiple|Forward Price-to-Revenue Multiple Exagen Inc.|Forward Price-to-Revenue Multiple MDXH|LUCD - Projected Price to Revenue|Price-to-Projected Revenue Ratio Prenetics (PRE)|Price-to-Projected Revenue Ratio IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Forward Price-to-Revenue Multiple|prophaselabs.com - Price-to-Projected Revenue Ratio|AIMD - Price-to-Projected Revenue Ratio|Co-Diagnostics Inc (CODX) - Forward Price-to-Revenue Multiple|HSCS: Forward P/S Multiple|BMRA - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CDIO|Market Cap to Future Revenue Ratio onconetix.gcs-web.com ONCO|Price-to-Projected Revenue Ratio Virax Biolabs (VRAX)|Price to Expected Revenue Ratio BJDX|Price-to-Projected Revenue Ratio Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Projected Revenue|Market Cap to Future Revenue Ratio FRES|Market Cap to Future Revenue Ratio GTG Labs (GENE)|ME (23andme.com) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Inc